Voxelotor-induced pulmonary embolism - 31/10/24

Doi : 10.1016/j.therap.2024.10.050

Pauline Schiro ^a,^{^{1
Members of the French Pharmacovigilance Network.},}⁎ , Romain Barus ^a,^{^{1
Members of the French Pharmacovigilance Network.}}, Laurent Chouchana ^b,^{^{1
Members of the French Pharmacovigilance Network.}}, Rayane Sari ^b,^{^{1
Members of the French Pharmacovigilance Network.}}, Pierre Cougoul ^c, François Montastruc ^a,^d,^{^{1
Members of the French Pharmacovigilance Network.}}, Haleh Bagheri ^a,^{^{1
Members of the French Pharmacovigilance Network.}}
^a Department of Medical and Clinical Pharmacology, Centre of Pharmacovigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, 31000 Toulouse, France
^b Department of Medical and Clinical Pharmacology, Centre of Pharmacovigilance and Pharmacoepidemiology, Cochin Hospital, Centre – Université de Paris, AP–HP, 75014 Paris, France
^c Internal Medicine Department, Toulouse University Hospital (CHU), Cancer University Institute of Toulouse-Oncopole, 31000 Toulouse, France
^d INSERM, UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, CIC 1426 - University Paul Sabatier Toulouse, 31000 Toulouse, France

^⁎Corresponding author. Department of Medical and Clinical Pharmacology, Centre of Pharmacovigilance and Pharmacoepiemiology, Faculty of Medicine, 37, allées Jules Guesde, 31000 Toulouse, FranceDepartment of Medical and Clinical Pharmacology, Centre of Pharmacovigilance and Pharmacoepiemiology, Faculty of Medicine37, allées Jules-GuesdeToulouse31000France

Le texte complet de cet article est disponible en PDF.

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Thursday 31 October 2024

Keywords : Voxelotor, Pulmonary embolism, Adverse drug reaction reporting systems for sickle cell disease

Le texte complet de cet article est disponible en PDF.

Plan

Data availability statement

Disclosure of interest

Sources of funding

☆	These cases have been anonymously reported to the French pharmacovigilance system on February 22, 2024 under the references FR-AFSSAPS-TO2024000359 and FR-AFSSAPS-TO2024000361.

Export

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Voxelotor-induced pulmonary embolism - 31/10/24

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL